AGBL3 and rheumatoid arthritis: The data were evaluated in an initial sample set comparing all three groups called “cohort 1” (anti-CCP3(−) n = 21, At-Risk n = 20, Early RA n = 5) and a confirmatory “cohort 2” (anti-CCP3(−) n = 31, At-Risk n = 36, Early RA n = 17), with 789,935 filtered loci for initial validation (Fig. 1a).